Actelion Statement on Letter by one of its Shareholders
(Thomson Reuters ONE) -
Actelion Pharmaceuticals Ltd /
Actelion Statement on Letter by one of its Shareholders
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
ALLSCHWIL/BASEL, SWITZERLAND - 2 May 2011 - Actelion (SIX: ATLN) announced that
it has taken note of a letter in which one of its major shareholders criticizes
the handling of - among others - disclosure and other reporting requirements in
relation to ongoing litigation in the United States. Respectfully, the company
believes that these criticisms have no factual basis.
This letter was issued ahead of the final jury deliberations in the ongoing
litigation in the United States (Asahi Kasei Pharma Corp. v. Actelion Ltd., case
number CIV 478533, Superior Court of the State of California, County of San
Mateo). On Friday, the jury awarded Asahi up to USD 547 million. On Tuesday, the
jury will continue deliberations regarding potential punitive awards.
The company is disappointed, but respectful of the jury`s verdict in this
ongoing litigation. Once the jury has concluded their deliberations, Actelion
will decide on potential further steps, including (but not limited to) an
appeal.
Also after jury deliberations have concluded, Actelion will be in a position to
address the criticisms made in the letter.
###
Notes to the Editor
About the complaint
On November 19, 2008, plaintiff Asahi Kasei Pharma Corporation ("Asahi") filed a
complaint at the State Court in California, US, against Actelion Ltd and its
subsidiaries Actelion Pharmaceuticals US Inc., Actelion Pharmaceuticals Ltd,
Actelion US Holding Company, CoTherix, Inc. ("CoTherix") and three individual
officers. The action arises from a dispute involving the license and development
agreement between Asahi and CoTherix for the drug compound fasudil that has been
terminated upon the acquisition of CoTherix in 2007.
Actelion Ltd.
Actelion Ltd is a biopharmaceutical company with its corporate headquarters in
Allschwil/Basel, Switzerland. Actelion's first drug Tracleer®, an orally
available dual endothelin receptor antagonist, has been approved as a therapy
for pulmonary arterial hypertension. Actelion markets Tracleer® through its own
subsidiaries in key markets worldwide, including the United States (based in
South San Francisco), the European Union, Japan, Canada, Australia and
Switzerland. Actelion, founded in late 1997, is a leading player in innovative
science related to the endothelium - the single layer of cells separating every
blood vessel from the blood stream. Actelion's over 2,400 employees focus on the
discovery, development and marketing of innovative drugs for significant unmet
medical needs. Actelion shares are traded on the SIX Swiss Exchange (ticker
symbol: ATLN) as part of the Swiss blue-chip index SMI (Swiss Market Index
SMI®).
For further information please contact:
Roland Haefeli
Vice President, Head of Investor Relations & Public Affairs
Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil
+41 61 565 62 62
+1 650 624 69 36
www.actelion.com
The above information contains certain "forward-looking statements", relating to
the company's business, which can be identified by the use of forward-looking
terminology such as "estimates", "believes", "expects", "may", "are expected
to", "will", "will continue", "should", "would be", "seeks", "pending" or
"anticipates" or similar expressions, or by discussions of strategy, plans or
intentions. Such statements include descriptions of the company's investment and
research and development programs and anticipated expenditures in connection
therewith, descriptions of new products expected to be introduced by the company
and anticipated customer demand for such products and products in the company's
existing portfolio. Such statements reflect the current views of the company
with respect to future events and are subject to certain risks, uncertainties
and assumptions. Many factors could cause the actual results, performance or
achievements of the company to be materially different from any future results,
performances or achievements that may be expressed or implied by such forward-
looking statements. Should one or more of these risks or uncertainties
materialize, or should underlying assumptions prove incorrect, actual results
may vary materially from those described herein as anticipated, believed,
estimated or expected.
--- End of Message ---
Actelion Pharmaceuticals Ltd
Gewerbestrasse 16 Allschwil Switzerland
ISIN: CH0010532478;
Press Release PDF:
http://hugin.info/131801/R/1511276/446597.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Actelion Pharmaceuticals Ltd via Thomson Reuters ONE
[HUG#1511276]
Unternehmensinformation / Kurzprofil:
Datum: 02.05.2011 - 07:00 Uhr
Sprache: Deutsch
News-ID 54101
Anzahl Zeichen: 5944
contact information:
Town:
Allschwil
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 172 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Actelion Statement on Letter by one of its Shareholders"
steht unter der journalistisch-redaktionellen Verantwortung von
Actelion Pharmaceuticals Ltd (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
